PHARMACOGENETIC ANALYSIS OF ANTIEPILEPTIC DRUGS FROM THE NATIONAL LIST OF ESSENTIAL DRUGS

Abstract

Epilepsy is the most common chronic neurological disorder and, although antiepileptic drugs control seizures, therapeutic failures and adverse effects are frequent. Pharmacogenetics emerges as a tool to personalize treatment. This study aimed to conduct a literature review on the antiepileptic drugs included in RENAME 2024. Articles were selected from the PubMed database (2014–2024) that related pharmacogenetics to RENAME-listed antiepileptics. Variants were identified in genes such as ABCB1, ABCC2, SCN1A, CYP2C9, CYP2C19, CYP3A4, UGT1A4, UGT2B7, and NAT2, associated with resistance, adverse reactions, and dose adjustment. The incorporation of pharmacogenetic testing into the Brazilian Unified Health System (SUS) may increase efficacy, reduce risks, and improve the quality of life of patients with epilepsy